MedCap AB (OSTO:MCAP) Piotroski F-Score: 5 (As of Jul. 17, 2026) — 17% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:MCAP MedCap AB OSTO:MCAP
81 GF Score
Price kr519.50
GF Value kr556.75
Valuation Fairly Valued
View Full Analysis

What is MedCap AB Piotroski F-Score?

MedCap AB OSTO:MCAP +2.87% 81 Piotroski F-Score is 5 as of Jul. 17, 2026, which is 17% below its 10-year median of 6.00. GuruFocus rates OSTO:MCAP with a GF Score™ of 81/100 and a GF Value™ of kr556.75 (Fairly Valued). Among 803 Medical Devices & Instruments companies, MedCap AB ranks better than 65.38% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

MedCap AB has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for MedCap AB's Piotroski F-Score or its related term are showing as below:

OSTO:MCAP' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 6   Max: 9
Current: 5

During the past 13 years, the highest Piotroski F-Score of MedCap AB was 9. The lowest was 3. And the median was 6.

MedCap AB  (OSTO:MCAP) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


MedCap AB Piotroski F-Score Related Terms


MedCap AB Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for MedCap AB's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MedCap AB Piotroski F-Score Chart

MedCap AB Annual Data
Trend Apr16 Apr17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.00 6.00 6.00 6.00 4.00

MedCap AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 5.00 3.00 4.00 5.00

OSTO:MCAP vs ABT, SYK, MDT: Piotroski F-Score Comparison

For the Medical Devices subindustry, MedCap AB's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MedCap AB Piotroski F-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, MedCap AB's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where MedCap AB's Piotroski F-Score falls into.


OSTO:MCAP
81GF Score
MedCap AB OSTO:MCAP
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 53.6 + 51.2 + 64.6 + 55.9 = kr225 Mil.
Cash Flow from Operations was 73.9 + 61.9 + 151.5 + 51.7 = kr339 Mil.
Revenue was 521.7 + 501.5 + 591 + 556.6 = kr2,171 Mil.
Gross Profit was 307 + 287.5 + 350.6 + 337.9 = kr1,283 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(2033.4 + 2090.4 + 2480.8 + 2606 + 2697.1) / 5 = kr2381.54 Mil.
Total Assets at the begining of this year (Mar25) was kr2,033 Mil.
Long-Term Debt & Capital Lease Obligation was kr390 Mil.
Total Current Assets was kr1,092 Mil.
Total Current Liabilities was kr520 Mil.
Net Income was 56.8 + 52.9 + 41.6 + 50.5 = kr202 Mil.

Revenue was 457.7 + 413.1 + 474.2 + 493.8 = kr1,839 Mil.
Gross Profit was 275.5 + 237.8 + 270.9 + 291.1 = kr1,075 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(1771.4 + 1890.7 + 1894.1 + 1991.4 + 2033.4) / 5 = kr1916.2 Mil.
Total Assets at the begining of last year (Mar24) was kr1,771 Mil.
Long-Term Debt & Capital Lease Obligation was kr286 Mil.
Total Current Assets was kr912 Mil.
Total Current Liabilities was kr341 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

MedCap AB's current Net Income (TTM) was 225. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

MedCap AB's current Cash Flow from Operations (TTM) was 339. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=225.3/2033.4
=0.11079965

ROA (Last Year)=Net Income/Total Assets (Mar24)
=201.8/1771.4
=0.11392119

MedCap AB's return on assets of this year was 0.11079965. MedCap AB's return on assets of last year was 0.11392119. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

MedCap AB's current Net Income (TTM) was 225. MedCap AB's current Cash Flow from Operations (TTM) was 339. ==> 339 > 225 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=390.3/2381.54
=0.16388555

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=285.7/1916.2
=0.14909717

MedCap AB's gearing of this year was 0.16388555. MedCap AB's gearing of last year was 0.14909717. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=1092.2/519.5
=2.10240616

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=912/341.3
=2.67213595

MedCap AB's current ratio of this year was 2.10240616. MedCap AB's current ratio of last year was 2.67213595. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

MedCap AB's number of shares in issue this year was 15.02. MedCap AB's number of shares in issue last year was 15.008. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=1283/2170.8
=0.59102635

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1075.3/1838.8
=0.58478355

MedCap AB's gross margin of this year was 0.59102635. MedCap AB's gross margin of last year was 0.58478355. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=2170.8/2033.4
=1.06757156

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=1838.8/1771.4
=1.038049

MedCap AB's asset turnover of this year was 1.06757156. MedCap AB's asset turnover of last year was 1.038049. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+0+0+0+1+1
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

MedCap AB has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 5 mean?
MedCap AB (OSTO:MCAP) has a Piotroski F-Score of 5 as of Jul. 17, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on MedCap AB and its competitors. This is 17% below median its historical median of 6.00. Over the past decade, MedCap AB's Piotroski F-Score has ranged from 3.00 to 9.00. According to the industry distribution chart, MedCap AB ranks #278 out of 803 companies in the Medical Devices & Instruments industry, placing it in the top 34.6%.
Is MedCap AB's Piotroski F-Score too high?
MedCap AB's current Piotroski F-Score of 5 is 17% below median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 9.00. The Medical Devices & Instruments industry median Piotroski F-Score is 5.00. MedCap AB's value of 5 is 0% at this industry median. Based on the distribution chart, MedCap AB ranks #278 out of 803 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, MedCap AB has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does MedCap AB's Piotroski F-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, MedCap AB ranks #278 out of 803 companies for Piotroski F-Score. This puts MedCap AB in the upper half of its industry. The industry median Piotroski F-Score is 5.00. MedCap AB's value of 5 is 0% at this benchmark. Historically, MedCap AB's own Piotroski F-Score has ranged from 3.00 to 9.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, MedCap AB has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Devices & Instruments company?
The median Piotroski F-Score among Medical Devices & Instruments companies is 5.00, based on 803 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MedCap AB's current Piotroski F-Score of 5 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on MedCap AB and its competitors. For the Medical Devices & Instruments industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MedCap AB's current Piotroski F-Score is 5, which is 17% below median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedCap AB stock overvalued right now?
Based on GuruFocus' analysis, MedCap AB (OSTO:MCAP) is currently considered Fairly Valued. The stock's GF Value™ is kr556.75, compared to a current price of kr519.50 — trading 6.7% below its estimated fair value. The current Piotroski F-Score is 5, which is 17% below median its 10-year median of 6.00 and 0% at the Medical Devices & Instruments industry median of 5.00. MedCap AB's overall GF Score™ is 81/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For MedCap AB (OSTO:MCAP), the current Piotroski F-Score is 5 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MedCap AB (OSTO:MCAP) Overvalued in 2026?

Based on GuruFocus' analysis, MedCap AB stock appears to be undervalued. The current stock price of kr519.50 is trading 6.7% below its estimated GF Value™ of kr556.75. GuruFocus considers MedCap AB to be Fairly Valued.

Key valuation signals for OSTO:MCAP:

  • Piotroski F-Score: 5 (17% below median its 10-year median of 6.00)
  • GF Value™: kr556.75 vs. price of kr519.50 (6.7% below fair value)
  • GF Score™: 81/100
  • Industry Position: 0% at the Medical Devices & Instruments median (#278 of 803)

No single metric tells the full story. See the OSTO:MCAP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


MedCap AB Business Description

Other Exchanges MCAPs:UK61MA:Germany
Address Sundbybergsvagen 1, Solna, SWE, 171 73
MedCap AB acquires and develops profitable, market-leading niche companies in the Nordic life science industry. It is diversified into two business areas namely Medical technology and Specialist medicines. Medical Technology mainly develops and sells various medical technology products and services. Its Specialist medicines develop and sell medicines within the regulatory classes of registered, extemporaneous and licensed medicines.
81GF Score

Get the complete analysis for OSTO:MCAP

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr519.50
Price
kr556.75
GF Value